- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI and Shionogi to cancel agreement
Ultrasound contrast agent developer Molecular Biosystems of SanDiego announced last week that it has exchanged breach-of-contractnotices with its Japanese licensee, Shionogi & Co. of Osaka.MBI said that the two companies have been unable to agree on
Ultrasound contrast agent developer Molecular Biosystems of San
Diego announced last week that it has exchanged breach-of-contract
notices with its Japanese licensee, Shionogi & Co. of Osaka.
MBI said that the two companies have been unable to agree on terms
for canceling their relationship, which covers distribution of
MBI's Albunex agent in Japan, Taiwan, and South Korea. MBI claims
that Shionogi has not diligently pursued the development and distribution
of Albunex in its territory, while Shionogi claims that MBI supplied
it with batches of Albunex that fail to meet adequate quality
standards. MBI said that it will pursue another licensee for Albunex
in the territory.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
